WO2022159593 … the present disclosure provides methods for treating idiopathic intracranial hypertension (IIH) or cluster headache (CH) in a subject in need thereof, comprising administering to the subject an effective intranasal amount of a somatostatin mimetic formulated for intranasal administration. In some embodiments, the intranasal administration is direct nose-to-brain administration.

WO2022182779 … a method is provided for treating idiopathic intracranial hypertension (IIH) or cluster headache (CH) in a subject in need thereof, comprising administering to the subject a therapeutically effective combination of: (a) an intranasal dosing regimen of a somatostatin mimetic, wherein the dosing regimen of the somatostatin mimetic provides a dose level or exposure that is less than the therapeutically effective dosing regimen when administered alone by a non-nasal route of administration; and (b) a dosing regimen of a carbonic anhydrase inhibitor, wherein the dosing regimen of the carbonic anhydrase inhibitor provides a dose level or exposure that is less than the therapeutically effective dose when administered alone. In some embodiments, the intranasal dosing regimen of the somatostatin mimetic is direct nose-to-brain administration.